Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity against human papillomavirus 16-associated tumor.

Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity against human papillomavirus 16-associated tumor.

Park, EK ; Kim, YW ; Lee, JM ; NamKoong, SE ; Kim, DG ; Chun, HJ ; Han, BD ; Bae, SM ; Jin, Hyun Sun ; Sin, JI ; Ahn, WS
Identifier: http://hdl.handle.net/2292/6229
Issue Date: 2005-02
Reference: Cancer Res Treat 37(1):63-70 Feb 2005
Rights: Copyright: 2005 Korean Cancer Association
Rights (URI): https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm

Abstract:

Human papillomavirus (HPV) infection has a significant role in cervical carcinogenesis, and HPV oncoprotein E7 plays an important part in the formation and maintenance of cervical cancer. Interleukin-12 (IL-12) has been reported to induce a cellular immune response, and to suppress the tumor growth and the E7 production. Here we describe the use of adenoviral delivery of the HPV 16 E7 subunit (AdE7) along with adenoviral delivery of IL-12 (AdIL-12) in mice with HPV-associated tumors.

Show full item record

Files in this item

Icon
DOI: 10.4143/crt.2005.37.1.63
Icon
Related URL: http://www.ncbi.nlm.nih.gov/pubmed/19956512
Find Full text

This item appears in the following Collection(s)

Share

Search ResearchSpace


Browse

Statistics